Title |
Direct reprogramming of fibroblasts into cardiomyocytes
|
---|---|
Published in |
Stem Cell Research & Therapy, May 2017
|
DOI | 10.1186/s13287-017-0569-3 |
Pubmed ID | |
Authors |
Yueqiu Chen, Ziying Yang, Zhen-Ao Zhao, Zhenya Shen |
Abstract |
Cardiovascular diseases are the leading causes of death in the world. The limited regenerative capacity of adult cardiomyocytes is the major barrier for heart regeneration. After myocardial infarction, myofibroblasts are the dominant cell type in the infarct zone. Therefore, it is a good idea to reprogram terminally differentiated myofibroblasts into cardiomyocyte-like cells directly, providing a good strategy to simultaneously reduce scar tissue and increase functional cardiomyocytes. Transcription factors were first identified to reprogram myofibroblasts into cardiomyocytes. Thereafter, microRNAs and/or small molecules showed great potential to optimize the reprogramming process. Here, we systemically summarize and compare the major progress in directed cardiac reprogramming including transcription factors and miRNAs, especially the small molecules. Furthermore, we discuss the challenges needed to be overcome to apply this strategy clinically. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Science communicators (journalists, bloggers, editors) | 1 | 50% |
Members of the public | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 169 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 24 | 14% |
Student > Bachelor | 24 | 14% |
Student > Ph. D. Student | 21 | 12% |
Student > Master | 20 | 12% |
Student > Doctoral Student | 13 | 8% |
Other | 30 | 18% |
Unknown | 37 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 56 | 33% |
Medicine and Dentistry | 23 | 14% |
Agricultural and Biological Sciences | 17 | 10% |
Engineering | 12 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 4% |
Other | 13 | 8% |
Unknown | 42 | 25% |